+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sexually Transmitted Infection Diagnostics Kit Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sexually Transmitted Infection Diagnostics Kit Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Sexually Transmitted Infection Diagnostics Kit Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081398
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Sexually transmitted infections (STIs) pose a significant public health challenge, driving demand for accurate, rapid, and accessible diagnostic solutions. Advances in pathogen detection have transformed the landscape, enabling early intervention and reducing transmission. This report delves into the evolving STI diagnostics kit market, examining key technological breakthroughs, regulatory and economic influences, and strategic imperatives. Through a comprehensive analysis, decision-makers will gain clarity on market dynamics, emerging opportunities, and potential risks. The following sections offer a structured exploration-beginning with transformative shifts, navigating the implications of U.S. tariffs, dissecting segmentation and regional insights, profiling leading companies, and concluding with actionable recommendations. This executive summary lays the foundation for informed strategic planning and investment in STI diagnostics.

Transformative Shifts Reshaping STI Diagnostic Solutions

Innovation in molecular techniques, point-of-care (POC) platforms, and connectivity solutions is reshaping the STI diagnostics arena. The transition from culture-based assays to nucleic acid amplification tests (NAATs) has elevated sensitivity and specificity, while multiplex panels allow simultaneous detection of multiple pathogens. Point-of-care testing has gained momentum, empowering clinicians with rapid turnaround times and facilitating decentralized screening initiatives. Digital integration-from cloud-based data management to AI-driven interpretive algorithms-optimizes workflow efficiency and enhances clinical decision support. Regulatory bodies continue to streamline pathways for novel platforms, accelerating time to market for disruptive technologies. Collectively, these shifts are driving a paradigm where diagnostics move closer to the patient, expanding access and improving outcomes.

Cumulative Impact of U.S. Tariffs on STI Diagnostic Imports

In 2025, newly implemented tariffs on diagnostic imports are altering cost structures and supply chain strategies. Section 301 duties and expanded classifications now encompass certain consumables, instruments, and reagents, prompting manufacturers to reassess sourcing. Elevated import costs have triggered price adjustments, pressuring profit margins and incentivizing nearshoring initiatives. Distributors are adjusting inventory buffers to mitigate lead-time risks, while end users face potential reimbursement challenges as payers scrutinize device and kit costs. In response, several industry players are forging local partnerships and exploring domestic manufacturing investments. These strategic adaptations aim to balance tariff-related headwinds with the imperative to maintain accessibility and affordability of STI testing.

Key Segmentation Insights Driving Market Dynamics

When examining the market by infection type, three primary categories emerge: bacterial, parasitic, and viral infections. Bacterial infections-specifically Chlamydia, Gonorrhea, and Syphilis-account for a significant proportion of diagnosed cases, driving demand for sensitive detection kits. Parasitic infection analysis, with an emphasis on Trichomoniasis, underscores the need for cost-effective, rapid assays in both clinical and community settings. Viral infections cover a diverse array of targets such as Hepatitis B, Herpes simplex virus, HIV, and HPV, each requiring specialized platforms for accurate screening and viral load monitoring.

When assessing product type, consumables and accessories-including sample collection surfaces and swabs-constitute fundamental inputs, while instruments such as laboratory analyzers and microscopes form the backbone of diagnostic workflows. Reagents and kits, encompassing detection kits and enzyme substrates, represent the core assay components; innovation in reagent stability and multiplex capability is a key differentiator among suppliers.

When considering test type, laboratory testing remains anchored by established modalities: chemiluminescent immunoassays, direct fluorescent antibody tests, enzyme immunoassays, and NAATs deliver high-throughput, centralized processing. Conversely, point-of-care testing is expanding rapidly through adoption of biosensor-based tests, rapid diagnostic tests, and strip-based assays, enabling same-visit decision making and outreach screening programs.

When evaluating end users, clinics continue to serve as primary access points for STI diagnostics, supported by diagnostic laboratories with advanced instrumentation and throughput capacity. Hospitals integrate STI testing into broader infectious disease panels, while the home use segment-propelled by self-testing kits-has surged, offering privacy and convenience for consumers seeking confidential screening.

When viewed through the mode of testing lens, home testing disrupts traditional models by delivering self-testing kits directly to users, laboratory testing retains its position for complex, confirmatory assays, and point-of-care testing harnesses rapid tests to bridge gaps between patient presentation and diagnosis, particularly in resource-limited settings.

When segmented by technology, immunology techniques such as enzyme-linked immunosorbent assay and Western blotting provide reliable serological assessments, whereas molecular diagnostics platforms leveraging next-generation sequencing and polymerase chain reaction deliver unparalleled sensitivity, rapid turnaround, and multiplexing capabilities for comprehensive pathogen detection.

Finally, when stratifying by sample type, blood samples-processed into plasma or serum-remain predominant for serology and molecular testing, swab samples including throat and urethral swabs are essential for site-specific pathogen identification, and urine samples offer a non-invasive alternative favored in large-scale screening and self-collection programs.

Regional Highlights: Americas, EMEA, and Asia-Pacific Trends

The Americas lead global investment in STI diagnostics, anchored by substantial public and private funding for advanced molecular platforms and expansive point-of-care networks. The United States maintains dominance through robust regulatory support and reimbursement frameworks, while Canada’s integrated healthcare systems foster streamlined adoption. Latin American markets are witnessing nascent growth driven by rising awareness campaigns and targeted funding to control endemic infection rates.

Europe, Middle East & Africa present a heterogeneous landscape. Western Europe emphasizes regulatory harmonization and accelerated in vitro diagnostic approvals, supporting innovative assay launches. The Middle East is investing in healthcare infrastructure upgrades, spurring demand for rapid and multiplex testing solutions. Conversely, Africa’s market faces challenges related to limited laboratory capacity, but public-private partnerships and donor programs are catalyzing decentralized screening initiatives to tackle high STI prevalence.

Asia-Pacific represents one of the fastest-growing regions, propelled by the high disease burden in China and India, increasing healthcare expenditure, and government initiatives to scale up diagnostic coverage. Local manufacturing hubs in China are rapidly expanding production capacities, while Southeast Asian nations are prioritizing point-of-care testing integration in primary healthcare. Japan and Australia exhibit mature markets with demand for cutting-edge molecular diagnostics and automation.

Leading Company Strategies and Competitive Landscape

Global diagnostic leaders such as Abbott Laboratories and Roche Diagnostics leverage vertically integrated portfolios, offering comprehensive molecular platforms, immunoassays, and digital connectivity solutions. Thermo Fisher Scientific and Qiagen N.V. focus on molecular diagnostics reagents and automation, supporting high-throughput laboratory demands. Siemens Healthineers and Becton, Dickinson and Company deploy robust instrument analyzers and sample collection systems, emphasizing workflow efficiency and regulatory compliance.

Specialized molecular innovators including Cepheid, Inc., GenMark Diagnostics, Inc., and Luminex Corporation drive market adoption of cartridge-based NAATs and multiplex bead-based assays, catering to decentralized and laboratory settings. bioMérieux SA and Hologic, Inc. continue to refine rapid immunodiagnostic tests for key bacterial and viral targets, while QuidelOrtho Corporation enhances point-of-care capabilities with ultrasensitive lateral flow assays.

Instrument and automation providers such as Tecan Trading AG and Grifols, S.A. support laboratory workflow integration through liquid handling and assay development services. OraSure Technologies, Inc. specializes in saliva-based collection devices and self-testing kits, targeting the home use segment. Across the competitive landscape, strategic partnerships, mergers, and targeted R&D investments underscore each company’s commitment to advancing STI diagnostics.

Actionable Recommendations for Industry Leaders

Invest in modular, scalable point-of-care platforms that accommodate multiplex panels for simultaneous detection of bacterial, viral, and parasitic pathogens to meet rising demand for decentralized screening. Diversify supply chains by establishing regional manufacturing hubs and alternative sourcing agreements to mitigate tariff pressures and logistics disruptions. Forge strategic alliances with public health agencies, academic institutions, and digital health providers to co-develop integrated solutions that combine diagnostics with real-time data analytics and telemedicine capabilities. Prioritize regulatory alignment across key markets by engaging early with health authorities and leveraging harmonized submission pathways to accelerate product approvals. Expand the home testing portfolio by innovating user-friendly self-collection devices and digital companion applications that enhance patient compliance and linkage to care. Penetrate emerging markets through tiered pricing models and mobile testing initiatives, ensuring affordability while maintaining quality standards.

Conclusion: Navigating the Future of STI Diagnostics

The STI diagnostics kit market stands at an inflection point, driven by technological innovation, shifting regulatory frameworks, and evolving healthcare delivery models. Stakeholders who embrace adaptability-through agile supply chains, strategic collaborations, and investment in decentralized testing-will capture significant market share and address unmet clinical needs. By aligning product development with patient-centric approaches and leveraging digital integration, companies can streamline workflows, reduce time-to-result, and enhance care linkage. Navigating tariff implications demands proactive supply chain resilience, while regional expansion hinges on tailored strategies that reflect local epidemiology and infrastructure. Ultimately, a balanced focus on performance, accessibility, and strategic partnerships will define success in this dynamic sector.

Market Segmentation & Coverage

This research report categorizes the Sexually Transmitted Infection Diagnostics Kit Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Bacterial Infections
    • Chlamydia Infections
    • Gonorrhea
    • Syphilis
  • Parasitic Infections
    • Trichomoniasis
  • Viral Infections
    • Hepatitis B Virus (HBV)
    • Herpes Simplex Virus (HSV)
    • Human Immunodeficiency Virus (HIV)
    • Human Papillomavirus (HPV)
  • Consumables & Accessories
    • Sample Collection Surfaces
    • Swabs
  • Instruments
    • Laboratory Analyzers
    • Microscopes
  • Reagents & Kits
    • Detection Kits
    • Enzyme Substrates
  • Laboratory Testing
    • Chemiluminescent Immunoassays (CLIAs)
    • Direct Fluorescent Antibody Tests (DFAs)
    • Enzyme Immunoassays (EIAs)
    • Nucleic Acid Amplification Tests (NAATs)
  • Point-Of-Care Testing
    • Biosensor-Based Tests
    • Rapid Diagnostic Tests
    • Strip-Based Assays
  • Clinics
  • Diagnostic Laboratories
  • Home Use
    • Self-Testing Kits
  • Hospitals
  • Home Testing
    • Self-Testing Kits
  • Laboratory Testing
  • Point Of Care Testing
    • Rapid Tests
  • Immunology Techniques
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Western Blotting
  • Molecular Diagnostics
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
  • Blood Samples
    • Plasma
    • Serum
  • Swab Samples
    • Throat Swabs
    • Urethral Swabs
  • Urine Samples

This research report categorizes the Sexually Transmitted Infection Diagnostics Kit Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Sexually Transmitted Infection Diagnostics Kit Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • Becton, Dickinson and Company (BD)
  • bioMérieux SA
  • Cepheid, Inc.
  • GenMark Diagnostics, Inc.
  • Grifols, S.A.
  • Hologic, Inc.
  • Luminex Corporation
  • OraSure Technologies, Inc.
  • Qiagen N.V.
  • QuidelOrtho Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sexually Transmitted Infection Diagnostics Kit Market, by Infection Type
8.1. Introduction
8.2. Bacterial Infections
8.2.1. Chlamydia Infections
8.2.2. Gonorrhea
8.2.3. Syphilis
8.3. Parasitic Infections
8.3.1. Trichomoniasis
8.4. Viral Infections
8.4.1. Hepatitis B Virus (HBV)
8.4.2. Herpes Simplex Virus (HSV)
8.4.3. Human Immunodeficiency Virus (HIV)
8.4.4. Human Papillomavirus (HPV)
9. Sexually Transmitted Infection Diagnostics Kit Market, by Product Type
9.1. Introduction
9.2. Consumables & Accessories
9.2.1. Sample Collection Surfaces
9.2.2. Swabs
9.3. Instruments
9.3.1. Laboratory Analyzers
9.3.2. Microscopes
9.4. Reagents & Kits
9.4.1. Detection Kits
9.4.2. Enzyme Substrates
10. Sexually Transmitted Infection Diagnostics Kit Market, by Test Type
10.1. Introduction
10.2. Laboratory Testing
10.2.1. Chemiluminescent Immunoassays (CLIAs)
10.2.2. Direct Fluorescent Antibody Tests (DFAs)
10.2.3. Enzyme Immunoassays (EIAs)
10.2.4. Nucleic Acid Amplification Tests (NAATs)
10.3. Point-Of-Care Testing
10.3.1. Biosensor-Based Tests
10.3.2. Rapid Diagnostic Tests
10.3.3. Strip-Based Assays
11. Sexually Transmitted Infection Diagnostics Kit Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Diagnostic Laboratories
11.4. Home Use
11.4.1. Self-Testing Kits
11.5. Hospitals
12. Sexually Transmitted Infection Diagnostics Kit Market, by Mode Of Testing
12.1. Introduction
12.2. Home Testing
12.2.1. Self-Testing Kits
12.3. Laboratory Testing
12.4. Point Of Care Testing
12.4.1. Rapid Tests
13. Sexually Transmitted Infection Diagnostics Kit Market, by Technology
13.1. Introduction
13.2. Immunology Techniques
13.2.1. Enzyme-Linked Immunosorbent Assay (ELISA)
13.2.2. Western Blotting
13.3. Molecular Diagnostics
13.3.1. Next-Generation Sequencing (NGS)
13.3.2. Polymerase Chain Reaction (PCR)
14. Sexually Transmitted Infection Diagnostics Kit Market, by Sample Type
14.1. Introduction
14.2. Blood Samples
14.2.1. Plasma
14.2.2. Serum
14.3. Swab Samples
14.3.1. Throat Swabs
14.3.2. Urethral Swabs
14.4. Urine Samples
15. Americas Sexually Transmitted Infection Diagnostics Kit Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Sexually Transmitted Infection Diagnostics Kit Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Sexually Transmitted Infection Diagnostics Kit Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. Becton, Dickinson and Company (BD)
18.3.3. bioMérieux SA
18.3.4. Cepheid, Inc.
18.3.5. GenMark Diagnostics, Inc.
18.3.6. Grifols, S.A.
18.3.7. Hologic, Inc.
18.3.8. Luminex Corporation
18.3.9. OraSure Technologies, Inc.
18.3.10. Qiagen N.V.
18.3.11. QuidelOrtho Corporation
18.3.12. Roche Diagnostics
18.3.13. Siemens Healthineers
18.3.14. Tecan Trading AG
18.3.15. Thermo Fisher Scientific Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET MULTI-CURRENCY
FIGURE 2. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET MULTI-LANGUAGE
FIGURE 3. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CHLAMYDIA INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TRICHOMONIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HEPATITIS B VIRUS (HBV), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE COLLECTION SURFACES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MICROSCOPES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DETECTION KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ENZYME SUBSTRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAYS (CLIAS), BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DIRECT FLUORESCENT ANTIBODY TESTS (DFAS), BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ENZYME IMMUNOASSAYS (EIAS), BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BIOSENSOR-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STRIP-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SELF-TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SELF-TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY WESTERN BLOTTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY THROAT SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URETHRAL SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY URINE SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 147. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 148. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 149. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 150. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 151. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 152. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 153. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 154. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 155. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 156. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 157. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 158. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 160. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 161. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 162. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 163. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 165. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 166. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 167. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 168. CANADA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 170. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 175. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 177. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 178. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 179. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 180. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 182. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 183. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 184. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 185. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 187. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 188. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 189. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 190. MEXICO SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 207. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 209. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 210. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 211. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 212. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 213. UNITED STATES SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 229. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY VIRAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME USE, 2018-2030 (USD MILLION)
TABLE 250. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MODE OF TESTING, 2018-2030 (USD MILLION)
TABLE 251. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY HOME TESTING, 2018-2030 (USD MILLION)
TABLE 252. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY POINT OF CARE TESTING, 2018-2030 (USD MILLION)
TABLE 253. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY IMMUNOLOGY TECHNIQUES, 2018-2030 (USD MILLION)
TABLE 255. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 256. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 257. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 258. AUSTRALIA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY SWAB SAMPLES, 2018-2030 (USD MILLION)
TABLE 259. CHINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY INFECTION TYPE, 2018-2030 (USD MILLION)
TABLE 260. CHINA SEXUALLY TRANSMITTED INFECTION DIAGNOSTICS KIT MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2030 (USD MILLION)
TABLE 261. CHINA SEXUALLY TRANSMI

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company (BD)
  • bioMérieux SA
  • Cepheid, Inc.
  • GenMark Diagnostics, Inc.
  • Grifols, S.A.
  • Hologic, Inc.
  • Luminex Corporation
  • OraSure Technologies, Inc.
  • Qiagen N.V.
  • QuidelOrtho Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Diagnostic Kit for Luteinizing Hormone Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Diagnostic Kit for Luteinizing Hormone Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global, United States Global, United States
From
Sexually Transmitted Diseases Diagnostics Market by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV)), Test Types (Laboratory Testing, Point-of-Care Testing), Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Sexually Transmitted Diseases Diagnostics Market by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV)), Test Types (Laboratory Testing, Point-of-Care Testing), Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
North America Urinary Tract Infection Testing Market, By Country, By Competition Forecast & Opportunities, 2019-2029F - Product Image

North America Urinary Tract Infection Testing Market, By Country, By Competition Forecast & Opportunities, 2019-2029F

  • Report
  • 132 Pages
  • North America
From
STD Self-Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

STD Self-Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 187 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.